pubmed-article:8816884 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:8816884 | lifeskim:mentions | umls-concept:C0302592 | lld:lifeskim |
pubmed-article:8816884 | lifeskim:mentions | umls-concept:C1333404 | lld:lifeskim |
pubmed-article:8816884 | lifeskim:mentions | umls-concept:C0301872 | lld:lifeskim |
pubmed-article:8816884 | lifeskim:mentions | umls-concept:C1704419 | lld:lifeskim |
pubmed-article:8816884 | pubmed:issue | 9 | lld:pubmed |
pubmed-article:8816884 | pubmed:dateCreated | 1996-11-29 | lld:pubmed |
pubmed-article:8816884 | pubmed:abstractText | The local inflammatory tumor infiltrate related to cervical carcinoma has been shown to consist mainly of T lymphocytes and macrophages. In 5% to 40% of the cases, eosinophilic granulocytes from a major part of the tumor-infiltrating cells. The presence of a high percentage of eosinophilic granulocytes in the infiltrate might reflect a less effective antitumor response, resulting in a worse overall survival. In the present study, histological slides from 83 patients who had been treated for cervical squamous carcinoma were reviewed. Special emphasis was put on the presence of eosinophils in the tumor infiltrate and correlated with clinical outcome as a parameter of the strength of the host-antitumor response. Multivariate analysis showed that the presence of a large amount of eosinophils among the infiltrate was an independent parameter, predicting a worse overall survival in patients with tumor-negative lymph nodes and tumor-negative resection margins (n = 61). The presence of eosinophilic granulocytes might represent a less appropriate immune response based on a disturbed equilibrium between Th-1- and Th-2-mediated immune response. | lld:pubmed |
pubmed-article:8816884 | pubmed:language | eng | lld:pubmed |
pubmed-article:8816884 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8816884 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:8816884 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:8816884 | pubmed:month | Sep | lld:pubmed |
pubmed-article:8816884 | pubmed:issn | 0046-8177 | lld:pubmed |
pubmed-article:8816884 | pubmed:author | pubmed-author:FleurenG JGJ | lld:pubmed |
pubmed-article:8816884 | pubmed:author | pubmed-author:TrimbosJ BJB | lld:pubmed |
pubmed-article:8816884 | pubmed:author | pubmed-author:JansenF WFW | lld:pubmed |
pubmed-article:8816884 | pubmed:author | pubmed-author:ZwindermanA... | lld:pubmed |
pubmed-article:8816884 | pubmed:author | pubmed-author:HogendoornP... | lld:pubmed |
pubmed-article:8816884 | pubmed:author | pubmed-author:van DrielW... | lld:pubmed |
pubmed-article:8816884 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:8816884 | pubmed:volume | 27 | lld:pubmed |
pubmed-article:8816884 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:8816884 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:8816884 | pubmed:pagination | 904-11 | lld:pubmed |
pubmed-article:8816884 | pubmed:dateRevised | 2005-11-17 | lld:pubmed |
pubmed-article:8816884 | pubmed:meshHeading | pubmed-meshheading:8816884-... | lld:pubmed |
pubmed-article:8816884 | pubmed:meshHeading | pubmed-meshheading:8816884-... | lld:pubmed |
pubmed-article:8816884 | pubmed:meshHeading | pubmed-meshheading:8816884-... | lld:pubmed |
pubmed-article:8816884 | pubmed:meshHeading | pubmed-meshheading:8816884-... | lld:pubmed |
pubmed-article:8816884 | pubmed:meshHeading | pubmed-meshheading:8816884-... | lld:pubmed |
pubmed-article:8816884 | pubmed:meshHeading | pubmed-meshheading:8816884-... | lld:pubmed |
pubmed-article:8816884 | pubmed:meshHeading | pubmed-meshheading:8816884-... | lld:pubmed |
pubmed-article:8816884 | pubmed:meshHeading | pubmed-meshheading:8816884-... | lld:pubmed |
pubmed-article:8816884 | pubmed:meshHeading | pubmed-meshheading:8816884-... | lld:pubmed |
pubmed-article:8816884 | pubmed:meshHeading | pubmed-meshheading:8816884-... | lld:pubmed |
pubmed-article:8816884 | pubmed:year | 1996 | lld:pubmed |
pubmed-article:8816884 | pubmed:articleTitle | Tumor-associated eosinophilic infiltrate of cervical cancer is indicative for a less effective immune response. | lld:pubmed |
pubmed-article:8816884 | pubmed:affiliation | Department of Gynecology, University of Leiden, The Netherlands. | lld:pubmed |
pubmed-article:8816884 | pubmed:publicationType | Journal Article | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8816884 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8816884 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8816884 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8816884 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8816884 | lld:pubmed |